ACTIVELLA
LOE ApproachingNDAORALTABLET
Approved
Dec 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ACTIVELLA by Novo Nordisk is characteristics. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar, vaginal atrophy due to menopause limitations of use :, vaginal atrophy due to menopause and 1 more indications. First approved in 2006.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTIVELLA is an oral hormone replacement therapy combining estradiol and norethindrone acetate, indicated for postmenopausal symptoms, endometrial hyperplasia prevention, and endometrial cancer risk reduction. It works by binding to estrogen and progesterone receptors to replace declining hormone levels and modulate gonadotropin secretion in postmenopausal women. The progestin component opposes estrogen effects on endometrial tissue, reducing hyperplasia risk.
$0.125MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal claims volume, indicating shrinking team focus and reduced promotional investment.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (4)
Worked on ACTIVELLA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.